Valuation
- Market cap
- 14,000
- Revenue TTM
- $280,000
- Net income TTM
- $-2,050,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -732.14%
- Debt to equity
- -0.63
Trading
- Volume
- 1,000
- Avg volume
- 93,008
- Day's range
- $0.00 – $0.00
- Shares out
- 144,100,000
- Stochastic %K
- 50%
- Beta
- 2.53
- Analysts
- —
- Price target
- $2.50
Company profile
Q BioMed Inc. engages in the acquisition, development, and financing of biomedical assets. The company offers Strontium Chloride Sr-89/Metastron, a radiopharmaceutical for the treatment of metastatic cancer bone pain. It also develops various preclinical candidates comprising QBM-001 for rare pediatric non-verbal autism spectrum disorder; UTTROSIDE-B, a chemotherapeutic for liver cancer; and MAN-01, a topical eyedrop...
Show more
Q BioMed Inc. engages in the acquisition, development, and financing of biomedical assets. The company offers Strontium Chloride Sr-89/Metastron, a radiopharmaceutical for the treatment of metastatic cancer bone pain. It also develops various preclinical candidates comprising QBM-001 for rare pediatric non-verbal autism spectrum disorder; UTTROSIDE-B, a chemotherapeutic for liver cancer; and MAN-01, a topical eyedrops for glaucoma. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 646 889 2226
- Website
- https://www.qbiomed.com
- Address
- 366 Madison Avenue, 3rd Floor, New York, United States
Latest news
No headlines yet.
